WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522504

CAS#: 220725-87-1

Description: EGIS-8332 is a potent and selective non-competitive AMPA receptor antagonist. EGIS-8332 inhibits AMPA/kainate ion channels and cell death. EGIS-8332 inhibited AMPA currents in rat cerebellar Purkinje cells and inhibited the AMPA- and quisqualate-induced excitotoxicity in primary cultures of telencephalon neurons (IC(50)=5.1-9.0 microM), in vitro. EGIS-8332 seems suitable for further development for the treatment of epilepsy, ischaemia and stroke based on its efficacy in a variety of experimental disease models, and on its low side effect potential.

Chemical Structure

CAS# 220725-87-1

Theoretical Analysis

MedKoo Cat#: 522504
Name: EGIS-8332
CAS#: 220725-87-1
Chemical Formula: C20H18N4O3
Exact Mass: 362.13789
Molecular Weight: 362.389
Elemental Analysis: C, 66.29; H, 5.01; N, 15.46; O, 13.24

Price and Availability

Size Price Availability Quantity
Bulk inquiry

Synonym: EGIS-8332; EGIS 8332; EGIS8332.

IUPAC/Chemical Name: 7-Acetyl-5-(4-aminophenyl)-8-methyl-9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-8-carbonitrile


InChi Code: InChI=1S/C20H18N4O3/c1-12(25)24-20(2,10-21)9-14-7-17-18(27-11-26-17)8-16(14)19(23-24)13-3-5-15(22)6-4-13/h3-8H,9,11,22H2,1-2H3

SMILES Code: CC(N1C(C#N)(CC2=CC3=C(C=C2C(C4=CC=C(C=C4)N)=N1)OCO3)C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 362.389 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Kovács AD, Saje A, Wong A, Ramji S, Cooper JD, Pearce DA. Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. Neuropharmacology. 2012 Oct;63(5):769-75. doi: 10.1016/j.neuropharm.2012.05.040. Epub 2012 Jun 6. PubMed PMID: 22683643; PubMed Central PMCID: PMC3408822.

2: Kovács AD, Saje A, Wong A, Szénási G, Kiricsi P, Szabó E, Cooper JD, Pearce DA. Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease. Neuropharmacology. 2011 Feb-Mar;60(2-3):405-9. doi: 10.1016/j.neuropharm.2010.10.010. Epub 2010 Oct 29. PubMed PMID: 20971125; PubMed Central PMCID: PMC3174473.

3: Cooper JD. Moving towards therapies for juvenile Batten disease? Exp Neurol. 2008 Jun;211(2):329-31. doi: 10.1016/j.expneurol.2008.02.016. Epub 2008 Mar 4. Review. PubMed PMID: 18400221.

4: Kapus GL, Gacsályi I, Vegh M, Kompagne H, Hegedus E, Leveleki C, Hársing LG, Barkóczy J, Bilkei-Gorzó A, Lévay G. Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: effects of GYKI 52466 and its novel analogues. Psychopharmacology (Berl). 2008 Jun;198(2):231-41. doi: 10.1007/s00213-008-1121-z. Epub 2008 Mar 25. PubMed PMID: 18363046.

5: Kovács AD, Pearce DA. Attenuation of AMPA receptor activity improves motor skills in a mouse model of juvenile Batten disease. Exp Neurol. 2008 Jan;209(1):288-91. Epub 2007 Oct 25. PubMed PMID: 17963751; PubMed Central PMCID: PMC4418195.

6: Gigler G, Móricz K, Agoston M, Simó A, Albert M, Benedek A, Kapus G, Kertész S, Vegh M, Barkóczy J, Markó B, Szabó G, Matucz E, Gacsályi I, Lévay G, Hársing LG Jr, Szénási G. Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models. Br J Pharmacol. 2007 Sep;152(1):151-60. Epub 2007 Jul 2. PubMed PMID: 17603549; PubMed Central PMCID: PMC1978282.

7: Vegh MG, Kovács AD, Kovács G, Szabó G, Tihanyi K, Hársing LG Jr, Lévay G. The new 2,3-benzodiazepine derivative EGIS-8332 inhibits AMPA/kainate ion channels and cell death. Neurochem Int. 2007 Feb;50(3):555-63. Epub 2006 Dec 4. PubMed PMID: 17147974.

8: Matucz E, Móricz K, Gigler G, Benedek A, Barkóczy J, Lévay G, Hársing LG Jr, Szénási G. Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats. Brain Res. 2006 Dec 6;1123(1):60-7. Epub 2006 Oct 24. PubMed PMID: 17064671.

9: Gressens P, Spedding M, Gigler G, Kertesz S, Villa P, Medja F, Williamson T, Kapus G, Levay G, Szenasi G, Barkoczy J, Harsing LG Jr. The effects of AMPA receptor antagonists in models of stroke and neurodegeneration. Eur J Pharmacol. 2005 Sep 5;519(1-2):58-67. PubMed PMID: 16112106.

10: Matucz E, Móricz K, Gigler G, Simó A, Barkóczy J, Lévay G, Hársing LG Jr, Szénási G. Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia. Brain Res. 2004 Sep 3;1019(1-2):210-6. PubMed PMID: 15306255.